In conclusion, the inhibitory properties of CL4 demonstrate its potential usefulness as a lead compound for the design of a new class of anticancer drugs and may become a valuable addition to the repertoire of inhibitors that target cancers that overexpress EGFR. This evidence concerns the gene EGFR and cancer.